Compare the effectiveness and safety of risankizumab versus
ustekinumab for adult participants with moderate to severe
CD who have failed anti-TNF therapy. Risankizumab is being investigated for use in Crohn's disease, an unapproved use. Safety and effectiveness have not been established.

The QUASAR study is evaluating the safety and effectiveness the study medicine has in adults with ulcerative colitis (UC).

The reason for this study is to see if the study drug mirikizumab is safe and effective in participants with moderately to severely active Crohn's disease.

• To evaluate the effect of the prebiotic fiber inulin on the microbiome of children with IBD who have subclinical disease activity (patients with no symptoms but elevated fecal calprotectin)
• To evaluate the efficacy of the prebiotic fiber inulin in reducing gut inflammation (fecal calprotectin) in IBD

The primary objective of this study is to evaluate whether investigational cilofexor reduces the risk of fibrosis progression among non-cirrhotic adults with primary sclerosing cholangitis (PSC).

The purpose of the PURSUIT 2 study is to see if an investigational medicine is safe and effective for treating children and young adults with UC.

The purpose of this study is to compare the effects (both good and bad) of both Stelara and Humira for those that have Crohn's Disease.

The primary objective of this study is to evaluate the efficacy of oral ozanimod compared with placebo on the induction of clinical remission.

The primary objective of this study is to evaluate the efficacy of oral ozanimod compared with placebo on the induction of clinical remission.

The purpose of the FIGARO 301 and FIGARO 302 studies is to evaluate the effectiveness and safety of SHP647 in patients with moderate to severe Ulcerative Colitis (UC) in inducing remission of symptoms based on patient-reported outcomes and endoscopy results